Form 4: Strata Critical Medical Co-CEO Equity Vesting

Co-CEO and General Counsel Melissa M. Tomkiel acquired 630,264 shares following performance criteria satisfaction and withheld 321,750 shares for tax obligations.

Summary

• Melissa M. Tomkiel, Co-CEO and General Counsel of Strata Critical Medical, Inc., reported the acquisition of 630,264 shares of Class A common stock on April 23, 2026.
• The acquisition resulted from the certification of performance-based restricted stock units (PSUs) granted on March 20, 2025.
• On April 24, 2026, 321,750 shares were withheld by the company at a price of $4.92 per share to satisfy tax withholding obligations.
• Following these transactions, the reporting person holds a total of 1,922,504 shares of Class A common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard executive compensation vesting rather than a change in strategic direction or market outlook.

Positives

• Successful achievement of performance criteria related to previously granted PSUs indicates alignment with corporate objectives.
• The reporting person maintains a significant equity stake of 1,922,504 shares, demonstrating continued long-term commitment to the company.

Negatives

• The withholding of 321,750 shares for tax purposes represents a significant portion of the newly vested equity, though this is a standard administrative procedure.

Risks

• Future equity compensation is subject to the achievement of performance criteria, which may not be met.

Future Outlook

The filing does not provide forward-looking guidance regarding company operations or future financial performance.

Industry Context

StockSavvy.ai notes that the vesting of performance-based equity for executive leadership is a standard corporate governance practice, signaling that the company has met specific internal milestones set in the prior year.

Comparison to Industry Standards

• The use of performance-based restricted stock units (PSUs) is consistent with standard executive compensation packages in the medical technology and biotech sectors.
• Tax withholding via share reduction is a standard industry practice for managing executive tax liabilities upon vesting.

Stakeholder Impact

• The transaction confirms that executive performance targets were met, which may be viewed positively by shareholders as an indicator of operational progress.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Strata Critical Medical, SRTA, Form 4, Insider Trading, Equity Compensation, Performance-based Restricted Stock Units